A. Muntañola

613 | LIMITED‐STAGE MANTLE CELL LYMPHOMA: CLINICAL FEATURES, MANAGEMENT, AND OUTCOMES IN A MULTICENTER RETROSPECTIVE STUDY FROM SPAIN

S. D. R. V. Cozzarelli, Alfonso Valencia, Alba Cabirta Touzón, Ana Marín‐Niebla et autres

Introduction: Treatment (tx) of older adults (OA) with mantle cell lymphoma (MCL) is evolving rapidly.In OA ≥ 60 years (y), the ENRICH study recently showed an improved progressionfree survival (PFS) for ibrutinib-rituximab (IR) over R-CHOP, with similar PFS as bendamustine-R (BR).While chemo-free …

es (code pays fourni par la source)

257 | ZANUBRUTINIB IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL): EFFICACY AND SAFETY OF 101 SPANISH PATIENTS TREATED IN THE REAL‐WORLD ON BEHALF OF GELTAMO

Fernando Martín‐Moro, A. Muntañola, Xabier Gutiérrez, L. Morais et autres

month OS rate of 100%.Any-grade adverse events (AEs) occurred in 20 pts (91%); the most common (≥ 25%) were diarrhea, pneumonia, and pyrexia in 6 pts (27%) each.Grade 3 or 4 AEs occurred in 12 pts (55%); the most common was (≥ …

es (code pays fourni par la source)

A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Armando López‐Guillermo, Miguel Canales, Iván Dlouhy, Santiago Mercadal et autres

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00662948). Patients in PR or CR/CR[u] after R-CHOP were randomized …

es (code pays fourni par la source)

TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL

Alfredo Rivas‐Delgado, Cristina López, Ferran Nadeu, Marta Grau et autres

Background: Testicular diffuse large B-cell lymphoma (T-DLBCL) is an infrequent and aggressive lymphoma accounting for 1-2% of all non-Hodgkin's lymphomas. Although prognosis improved with the introduction of rituximab, the outcome of these patients is still poor. This study aimed to analyze the …

es (code pays fourni par la source)

OUTCOMES OF PATIENTS WITH LYMPHOMA AND COVID‐19: AN OBSERVATIONAL COHORT STUDY FROM GELTAMO SPANISH GROUP

Macarena Izuzquiza, Mariana Bastos‐Oreiro, Mónica Baile, Sara Nistal et autres

Introduction: COVID-19 is thought to be more frequent and severe in patients with cancer. Lymphoma patients may be especially vulnerable, due to the immunodeficiency and immune dysregulation caused by the lymphoma itself and the antitumor treatments. This study describes the characteristics and …

es (code pays fourni par la source)

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

Roser Velasco, Santiago Mercadal, Noemí Vidal, Mónica Alañá et autres

es (code pays fourni par la source)

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

Laura Magnano, Sara Alonso, Miguel Alcoceba, Alfredo Rivas‐Delgado et autres

The use of immunochemotherapy has improved the outcome of follicular lymphoma (FL). Recently, complete response at 30 months (CR30) has been suggested as a surrogate for progression-free survival. This study aimed to analyse the life expectancy of FL patients according to their …

es (code pays fourni par la source)

Life Expectancy of Follicular Lymphoma Patients in Complete Response at 30 Months is Similar to that of the Spanish General Population

Laura Magnano, Sara Alonso, Miguel Alcoceba, Alfredo Rivas‐Delgado et autres

es (code pays fourni par la source)

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

Alejandra Martínez‐Trillos, Magda Pinyol, Julio Delgado, Marta Aymerich et autres

Small lymphocytic lymphoma (SLL) is considered as the non-leukemic form of presentation of chronic lymphocytic leukemia (CLL). We have compared the features, genomic alterations, and outcome of 890 patients with CLL and SLL. One hundred and thirteen patients presented as SLL and …

es (code pays fourni par la source)

PATIENTS WITH FOLLICULAR LYMPHOMA (FL) IN MAINTAINED COMPLETE RESPONSE (CR) AT 30 MONTHS SHOW A SURVIVAL SIMILAR TO A SEX‐ AND AGE‐MATCHED SPANISH GENERAL POPULATION

Laura Magnano, Sara Alonso, Miguel Alcoceba, A. Muntañola et autres

73% of young patients vs 66%, p = 0.0021).The two groups had similar CR24 (32% vs 29%, p = 0.32), CR30 (31% vs 30%, p = 0.57), 5-year estimates for PFS of 44% (95% CI = 41-49 for young patients and 43-46 …

es (code pays fourni par la source)

Initial management of primary central nervous system lymphoma in Spain in the last decade. The experience of the GELTAMO and S panish neuro‐oncology groups

Santiago Mercadal, Noemí Vidal, Miriam López-Parra, Mariam Ibáñez et autres

Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). Introduction: Primary central nervous system lymphoma (PCNSL) is a challenging tumour frequently misdiagnosed and associated with a considerable diagnostic delay. Outcome of PCNSL patients not included in clinical trial may be …

es (code pays fourni par la source)

CLINICAL CHARACTERISTICS AND PROGNOSIS OF ELDERLY (>70 YEARS) FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: MULTICENTRE RETROSPECTIVE ANALYSIS OF THE GELTAMO SPANISH GROUP

Miguel Alcoceba, Laura Magnano, Sara Alonso, Marcio Andrade‐Campos et autres

With respect to myelotoxicity, 131 I-RIT had the lowest incidence of grade 3/4 neutropenia and, conversely, the highest incidence of grade 3/4 thrombocytopenia.The lowest incidence of thrombocytopenia was observed with RCHOP and was consistent across trials.MDS/AL was reported at 5-yr follow up …

es (code pays fourni par la source)